Prealbumin – Talk Bio

BridgeBio’s Attruby Gains FDA Approval, Challenging Pfizer’s Tafamidis in ATTR-CM Treatment

2 months ago talkbio0Tagged Acoramidis, Approved, ATTR-CM, Attruby, BridgeBio, Cardiomyopathies, Pfizer, Prealbumin, Stabilizer - function, tafamidis, United States Food and Drug Administration

Attruby, acoramidis, BridgeBio, ATTR-CM, tafamidis, Pfizer, FDA approval, transthyretin stabilizer, cardiomyopathy

Intellia Therapeutics Slashes Workforce by 27% to Focus on Late-Stage CRISPR Candidates Amid Challenging Market Environment

3 months ago talkbio0Tagged Amyloidosis, Angioedema, ATTR, Clustered Regularly Interspaced Short Palindromic Repeats, Commercialization strategy, Hereditary, Intellia, Late stage, nex-z, Nexiguran, NTLA-2002, Prealbumin, Workforce

Intellia Therapeutics, CRISPR, Workforce reduction, Late-stage drug candidates, NTLA-2002, Nexiguran ziclumeran (nex-z), Hereditary angioedema, Transthyretin (ATTR) amyloidosis, Commercialization strategy

FDA Approves Attruby (Acoramidis) for ATTR-CM, Offering New Hope for Patients with Transthyretin Cardiac Amyloidosis

5 months ago talkbio0Tagged Acoramidis, Approved, ATTR-CM, Attruby, BridgeBio Pharma, Heart Diseases, Prealbumin, Senile cardiac amyloidosis, United States Food and Drug Administration

Attruby, Acoramidis, FDA Approval, ATTR-CM, Transthyretin Cardiac Amyloidosis, BridgeBio Pharma, Heart Disease Treatment

CRISPR Gene Editing Therapy Can Be Administered Twice, Intellia Study Suggests

10 months ago talkbio0Tagged Amyloidosis, Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, gene therapy, Intellia, Prealbumin, re-dosing

CRISPR, gene editing, Intellia Therapeutics, transthyretin amyloidosis, gene therapy, re-dosing